Vortioxetine: Mechanism of Action, Side Effects, and Starting Dose
Start vortioxetine at 10 mg once daily for major depressive disorder in adults, with the option to initiate at 5 mg daily in patients who may not tolerate higher doses. 1
Mechanism of Action
Vortioxetine has a unique multimodal mechanism that distinguishes it from traditional SSRIs and SNRIs:
- Primary mechanism: Inhibits serotonin reuptake by binding with high affinity to the serotonin transporter (Ki=1.6 nM, IC50=5.4 nM) 1
- Additional receptor activities: Acts as a 5-HT3, 5-HT1D, and 5-HT7 receptor antagonist; 5-HT1B receptor partial agonist; and 5-HT1A receptor agonist 1, 2
- Selectivity: Does not significantly bind to norepinephrine (Ki=113 nM) or dopamine (Ki>1000 nM) transporters 1
- Clinical relevance: The combination of serotonin reuptake inhibition and direct receptor modulation is thought to enhance serotonergic activity in the CNS, though the exact contribution of each mechanism to antidepressant effects remains incompletely understood 1
The multimodal action may contribute to vortioxetine's effects on cognitive function in addition to mood symptoms 2, 3, 4.
Starting Dose and Dosing
The recommended starting dose is 10 mg once daily, administered orally without regard to food. 1
Dosing considerations:
- Standard range: 5-20 mg/day 1, 2, 3
- Initial lower dose option: May start at 5 mg daily in patients anticipated to have tolerability concerns, then increase to 10 mg as tolerated 1
- Dose adjustments: Can increase to 20 mg/day or decrease to 5 mg/day based on individual tolerability and response 1
- CYP2D6 poor metabolizers: Reduce maximum recommended dose to 10 mg/day due to higher plasma concentrations 1
- Pharmacokinetics: Linear and dose-proportional; terminal half-life approximately 66 hours with steady-state achieved within 2 weeks 1
Special populations:
- Elderly patients: No dose adjustment required based on age alone 1
- Hepatic/renal impairment: No dose adjustment needed for mild to moderate impairment 1
Side Effects
Common adverse effects (most frequent):
- Gastrointestinal: Nausea (most common), vomiting, diarrhea, constipation 1, 3, 5, 4
- Neurological: Dizziness, headache 3, 4
- Other: Dry mouth 4
Nausea is the most commonly reported side effect and the most frequent reason for discontinuation in clinical trials. 3, 5
Serious adverse effects requiring monitoring:
Suicidal thinking and behavior: All antidepressants, including vortioxetine, carry a boxed warning for increased risk of suicidal thoughts and behaviors in patients up to age 24 years 1. Close monitoring is essential, especially:
- Within the first 1-2 weeks of initiation 6
- During the first 1-2 months of treatment when risk is highest 6
- After any dose adjustments 1
- Monitor for emergence of agitation, irritability, or unusual behavioral changes 6
Serotonin syndrome: Can occur when combined with other serotonergic agents 6:
- Symptoms include mental status changes (confusion, agitation), neuromuscular hyperactivity (tremors, clonus, hyperreflexia), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis) 6
- Contraindicated with MAOIs (must allow 14 days between discontinuing MAOI and starting vortioxetine) 1
- Exercise caution when combining with other serotonergic drugs including SSRIs, SNRIs, TCAs, tramadol, triptans, and St. John's wort 6
Other serious but rare adverse effects:
- Abnormal bleeding (especially with concurrent NSAIDs or aspirin) 6
- Hyponatremia (particularly in elderly patients) 1
- Seizures 1
- Mania/hypomania activation 1
- Sexual dysfunction 1
Tolerability profile:
- Discontinuation rates: Similar to placebo in clinical trials 6
- Overall safety: Favorable tolerability profile compared to other antidepressants 3, 5
- Overdose: Limited experience; doses up to 80 mg associated with nausea, vomiting, dizziness, and diarrhea; one case of serotonin syndrome and one seizure reported at doses >80 mg 1
Drug interactions:
- Strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine): Reduce vortioxetine dose by half 1
- Strong CYP inducers (e.g., rifampin, carbamazepine, phenytoin): May require vortioxetine dose increase 1
- MAOIs: Absolute contraindication due to serotonin syndrome risk 1
Clinical Efficacy Context
Vortioxetine demonstrates significant efficacy in major depressive disorder:
- Response rates: Approximately 53% (vs. 35% placebo) 3
- Remission rates: Approximately 29% (vs. 19% placebo) 3
- Time to effect: Clinically significant improvement typically by week 6, with maximal improvement by week 12 6
- Cognitive benefits: May improve cognitive symptoms beyond standard antidepressants 2, 3, 5, 7
Continue treatment for 4-9 months after achieving satisfactory response in first-episode depression; longer duration for patients with recurrent episodes. 6